BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Solorel macimorelin: SPA received

Aeterna Zentaris received an SPA from FDA after amending the protocol for an ongoing, open-label, U.S. Phase III trial evaluating Solorel to diagnose AGHD. The trial, which had enrolled 42 AGHD patients and 10 healthy controls, will enroll an additional 30 healthy controls to be matched with AGHD...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >